CCR7(+) activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity.

CCR7(+) activated dendritic cells are crucial for both spontaneous and therapy-induced anti-tumor immune responses, with their ablation impairing tumor control.

• Why it matters: Understanding the specific immune cell states that drive effective anti-tumor responses can improve immunotherapy strategies and outcomes.
• What they did: Researchers used mouse models to selectively label or eliminate CCR7(+) activated dendritic cells (actDCs), analyzing their role in stimulating tumor-specific cytotoxic T lymphocytes (CTLs) through cross-presentation and cross-dressing.
• The result: The absence of actDCs reduced CTL activation and effector function within tumors, leading to diminished spontaneous tumor control and weakened responses to immune checkpoint blockade and adoptive T cell therapy, highlighting their essential role in anti-tumor immunity.